Latest Articles about ARIA

Ariad Posts Wider Y/Y Loss - Analyst Blog

Zacks Equity Research — Wed, 08 May 2013 18:23:32 Z

Ariad Pharmaceuticals, Inc. ( ARIA ) reported first quarter loss of 36 cents per share, wider than the year-ago loss of 25 cents per share but narrower than the Zacks Consensus Estimate of

Stock Downgrades: Get Rid of Ruckus After Noisy Quarter

Justin Sharon — Tue, 07 May 2013 17:27:00 Z

After last week's celebration of the Dow (^DJI) hitting 15,000, came the hangover. Although - considering alcoholic mint juleps were the order of the day for Saturday's Kentucky Derby, and

Ariad Presents Data on AP26113 - Analyst Blog

Zacks Equity Research — Sat, 13 Apr 2013 02:09:14 Z

Ariad Pharmaceuticals, Inc. ( ARIA ) recently presented pre-clinical data on AP26113. The data presented by the company revealed that AP26113 can inhibit clinically relevant anaplastic

More Data on Ariad's Iclusig - Analyst Blog

Zacks Equity Research — Thu, 11 Apr 2013 01:09:26 Z

Ariad Pharmaceuticals, Inc. ( ARIA ) recently presented pre-clinical data on Iclusig (ponatinib) at the annual meeting of the American Association for Cancer Research (AACR). The study

Pre-Clinical Data on Ariad's Iclusig - Analyst Blog

Zacks Equity Research — Wed, 10 Apr 2013 02:09:59 Z

Ariad Pharmaceuticals, Inc. ( ARIA ) recently presented pre-clinical data on Iclusig (ponatinib). The company presented data which showed that Iclusig has the potential to inhibit RET and

Ariad Pharma trader won't jump ship

David Russell — Tue, 09 Apr 2013 12:06:05 Z

Ariad Pharmaceuticals took a skid last month, but one investor isn't abandoning the stock. optionMONSTER's Heat Seeker monitoring system detected the purchase of 2,190 June 19 calls for $1 and

R&D and Iclusig Update from Ariad - Analyst Blog

Zacks Equity Research — Sat, 06 Apr 2013 02:08:24 Z

Ariad Pharmaceuticals, Inc. ( ARIA ) recently provided an update on its pipeline and the commercialization of Iclusig in the US. We remind investors that in Dec 2012, Iclusig gained the US

Stock Market News for April 2, 2013 - Market News

Zacks Equity Research — Tue, 02 Apr 2013 18:10:41 Z

A discouraging report on the manufacturing sector dragged major indices lower on Monday. In the previous week the S&P 500 had touched a new high but could not sustain that level

CHMP Positive on Ariad's Iclusig - Analyst Blog

Zacks Equity Research — Tue, 26 Mar 2013 02:27:49 Z

Ariad Pharmaceuticals Inc. ( ARIA ) recently announced that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has given a favorable opinion on the

Ariad Reports in line 4Q Loss - Analyst Blog

Zacks Equity Research — Wed, 27 Feb 2013 20:10:01 Z

Ariad Pharmaceuticals, Inc. ( ARIA ) reported fourth quarter loss of 36 cents per share, compared with the year-ago loss of 23 cents per share. The Zacks Consensus Estimate for the fourth

Pre-Market Earnings Report for February 25, 2013 : LOW, FE, HTZ, DCI, KOS, ARIA, DDD, BGC, CTB, CWH, HL, DNDN

NASDAQ.com News — Sat, 23 Feb 2013 02:00:03 Z

The following companies are expected to report earnings prior to market open on 02/25/2013. Visit our Earnings Calendar for a full list of expected earnings releases. Lowe's Companies, Inc.

ARIAD Closes Offering of Shares - Analyst Blog

Zacks Equity Research — Thu, 31 Jan 2013 01:40:01 Z

ARIAD Pharmaceuticals, Inc. ( ARIA ) recently announced the closure of its previously announced public offering. ARIAD Pharma priced the public offering of 15.3 million common shares at

ARIAD Announced Ponatinib Data - Analyst Blog

Zacks Equity Research — Mon, 17 Dec 2012 21:00:01 Z

ARIAD Pharmaceuticals ( ARIA ) recently announced positive data from the pivotal PACE study on ponatinib. ARIAD is evaluating the candidate for use in heavily pretreated patients, suffering

Jazz Initiates Erwinaze Trial - Analyst Blog

Zacks Equity Research — Wed, 05 Dec 2012 21:20:01 Z

Jazz Pharmaceuticals ( JAZZ ) recently initiated a study on Erwinaze (asparaginase Erwinia chrysanthemi) for the treatment of patients suffering from acute lymphoblastic leukemia (ALL) with

Data Published on ARIAD Candidate - Analyst Blog

Zacks Equity Research — Fri, 30 Nov 2012 23:15:01 Z

ARIAD Pharmaceuticals ( ARIA ) recently announced the publishing of results from a phase I dose-escalation study of ponatinib in the New England Journal of Medicine . Ponatinib, a